Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body × 130-nm albumin-bound paclitaxel × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06841354 2026-03-13

TroFuse-011

Phase 3 Recruiting

1,000 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

340 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT05017012 2026-01-08

MK-3475A-C18

Phase 1 Active not recruiting

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04956692 2024-12-03

MK-3475-A86

Phase 3 Active not recruiting

531 enrolled 18 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 2 FDA

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

Phase 3 Completed

559 enrolled 18 charts 1 FDA

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04530227 2020-11-13

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Phase 2 Unknown

30 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02622074 2020-09-10

KEYNOTE 173

Phase 1 Completed

60 enrolled 26 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Clinical Trials

MK-2870-010

TroFuse-011

KEYNOTE-B49

MK-3475A-C18

MK-3475-A86

KEYNOTE-355

KEYNOTE-407

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

KEYNOTE 173